Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

63
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
63
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

317
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
317
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

413
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
413
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

369
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

618
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
618
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.0K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with and without augmented renal clearance: A multicenter cohort.

Pharmacotherapy·2022
Same author

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates in a Hollow-Fibre Infection Model.

Antibiotics (Basel, Switzerland)·2022
Same author

Optimisation of treatments for oral <i>Neisseria gonorrhoeae</i> infection: Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial.

BMJ open·2022
Same author

Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches.

Transplant infectious disease : an official journal of the Transplantation Society·2022
Same author

Closed-loop control of continuous piperacillin delivery: An <i>in silico</i> study.

Frontiers in bioengineering and biotechnology·2022
Same author

Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation.

American journal of respiratory and critical care medicine·2022

Related Experiment Video

Updated: Mar 24, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Using PK/PD to optimize antibiotic dosing for critically ill patients.

Jason A Roberts1

  • 1Burns, Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, Australia. j.roberts2@uq.edu.au

Current Pharmaceutical Biotechnology
|May 11, 2011
PubMed
Summary

Optimizing antibiotic dosing for critically ill patients requires understanding altered pharmacokinetics due to organ dysfunction. Personalized dosing regimens, using Bayesian software with therapeutic drug monitoring and pathogen susceptibility data, are essential for effective treatment.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.3K
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
11:00

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

8.8K

Related Experiment Videos

Last Updated: Mar 24, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.3K
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
11:00

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress

Published on: August 31, 2015

8.8K

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Infectious Diseases

Background:

  • Critically ill patients exhibit unique pharmacokinetic differences compared to non-critically ill individuals.
  • Organ system dysfunction, particularly cardiovascular and renal, significantly alters antibiotic distribution and clearance.
  • Sub-therapeutic antibiotic concentrations can result from these pharmacokinetic changes, impacting treatment efficacy.

Purpose of the Study:

  • To review existing literature on antibiotic dosing requirements for critically ill patients.
  • To present a framework for optimizing antibiotic therapy in complex cases.
  • To achieve pharmacokinetic/pharmacodynamic targets for improved patient outcomes.

Main Methods:

  • Literature review of studies on antibiotic pharmacokinetics in critically ill populations.
  • Analysis of the impact of pathophysiology on drug disposition.
  • Discussion of a framework for rational antibiotic dosing.

Main Results:

  • Pathophysiology profoundly affects antibiotic volume of distribution and clearance in critically ill patients.
  • Cardiovascular and renal dysfunction are key factors leading to altered antibiotic concentrations.
  • Adherence to antibiotic pharmacodynamics is crucial in the face of altered pharmacokinetics.

Conclusions:

  • Personalized antibiotic dosing is necessary for critically ill patients due to altered pharmacokinetics.
  • In the absence of validated algorithms, Bayesian software integrating therapeutic drug monitoring and pathogen susceptibility data is recommended.
  • Tailored dosing regimens are essential for achieving optimal pharmacokinetic/pharmacodynamic targets and improving treatment outcomes.